Vaccines and Antiviral Therapies for Mpox Virus in Pregnant and Breastfeeding Women: Efficacy and Maternal–Child Outcomes DOI Creative Commons
Maryum Imran, Myra Sohail, Javeria Kamran

et al.

Viruses, Journal Year: 2025, Volume and Issue: 17(4), P. 456 - 456

Published: March 22, 2025

Mpox (formerly known as monkeypox), the major public health concern of 2022, has elicited much attention globally. In addition to usual symptoms observed in smallpox virus infections, infected mothers were found hold a possible risk transmission newborns during delivery. This review aimed summarize recent clinical trials that involved antiviral therapy, vaccines, immunoglobulin and other pharmacological interventions specifically for treating pregnant women. A comprehensive search was performed using databases such PubMed, Google Scholar, Medline find appropriate disease management strategies. Amongst vaccines antivirals being used treatment, Modified Vaccinia Ankara (MVA/MVA-BN) Lister clone 16-medium pocket size-8 (LC16m8), while prophylactically effective, have been deemed unsafe lactating females. Antivirals like Tecovirimat, on hand, are considered be better alternative, but they not without risks may outweigh potential benefits. Additionally, efforts reduce maternal fetal complications include administering MVA-BN vaccine awareness campaigns regarding herd immunity. Therefore, necessary precautions, prophylactic vaccinations high-risk outbreak regions, symptomatic treatment females currently appear more feasible approaches against mpox virus.

Language: Английский

Anti-Orthopoxvirus Activity of Amantadine and Rimantadine Derivatives—In Vitro Testing and Molecular Modeling DOI Creative Commons

Ivan A. Moskalev,

Е. А. Akishina, Е. А. Дикусар

et al.

Chemistry, Journal Year: 2025, Volume and Issue: 7(2), P. 34 - 34

Published: March 1, 2025

In 2022, the number of mpox cases spiked worldwide, leading to a surge in scientific research on members Orthopoxvirus genus and discovery new compounds exhibiting anti-orthopoxvirus activity. This work is devoted synthesis containing an adamantane fragment evaluation their activity against vaccinia virus, offering possible mechanism antiviral action synthesized agents. Among all studied derivatives, three (2, 4, 12) were found demonstrate highest activity, with most promising compound 2 (N-(adamantan-1-yl)isonicotinamide) having lowest toxicity level selectivity index (SI) 115. The pharmacophoric profiles these are similar profile tecovirimat, inhibitor membrane viral protein p37. Analysis results molecular modeling suggests that investigated can inhibit virus by suppressing phospholipase

Language: Английский

Citations

0
Mpox: Transmission, clinical manifestations, prevention, and treatment – a narrative review DOI

Erica Sandoval-Urbano,

Jhonny E. Pimentel-Betancourt,

Kelita M. Lozano-Gutierres

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: 3, P. 182 - 182

Published: Feb. 18, 2025

Objective:To identify the transmission methods, symptoms, complications, prevention, and treatment associated with Mpox. Design:Literature review based on a narrative synthesis. Data Sources:Web of Science, Google Scholar, Scielo, ScienceDirect, Redalyc, Scopus. Study Selection:Documents were selected analyzed through critical literature review, considering inclusion exclusion criteria. Results:A was conducted corpus 17 articles, including 11 reviews, 2 systematic 4 statistical analyses. Mpox is more prevalent among children, adults, pregnant women, homosexual bisexual individuals. The regions highest outbreak incidence are Asia, South America, Europe, United States, especially West Central Africa, where it endemic. Clinical conditions include fever, skin rashes, abdominal pain, meningitis, strongly linked to HIV. Most reported cases have been lower-class individuals, some from middle class. Conclusions: virus transmitted various means, primarily contact, bodily fluids, sexual relations between men. It significantly affects children women presents range lesions being most frequent, followed by headaches, oral lesions, others. If left untreated or inadequately managed, can lead severe HIV-positive individuals immunocompromised patients at risk. Pneumonia be fatal in cases. Good personal hygiene recommended, although there no approved vaccines for Mpox, Tecovirimat Brincidofovir show potential approval case future outbreaks.

Language: Английский

Citations

0
Vaccines and Antiviral Therapies for Mpox Virus in Pregnant and Breastfeeding Women: Efficacy and Maternal–Child Outcomes DOI Creative Commons
Maryum Imran, Myra Sohail, Javeria Kamran

et al.

Viruses, Journal Year: 2025, Volume and Issue: 17(4), P. 456 - 456

Published: March 22, 2025

Mpox (formerly known as monkeypox), the major public health concern of 2022, has elicited much attention globally. In addition to usual symptoms observed in smallpox virus infections, infected mothers were found hold a possible risk transmission newborns during delivery. This review aimed summarize recent clinical trials that involved antiviral therapy, vaccines, immunoglobulin and other pharmacological interventions specifically for treating pregnant women. A comprehensive search was performed using databases such PubMed, Google Scholar, Medline find appropriate disease management strategies. Amongst vaccines antivirals being used treatment, Modified Vaccinia Ankara (MVA/MVA-BN) Lister clone 16-medium pocket size-8 (LC16m8), while prophylactically effective, have been deemed unsafe lactating females. Antivirals like Tecovirimat, on hand, are considered be better alternative, but they not without risks may outweigh potential benefits. Additionally, efforts reduce maternal fetal complications include administering MVA-BN vaccine awareness campaigns regarding herd immunity. Therefore, necessary precautions, prophylactic vaccinations high-risk outbreak regions, symptomatic treatment females currently appear more feasible approaches against mpox virus.

Language: Английский

Citations

0